BRANDI TORRES: Open Payments
NPI 1104344282 · REFORM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$642 in 46 payments from 11 companies in 2025. Trend: 2023 $1,141 · 2024 $685 · 2025 $642
Food & beverage: $642
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $174 |
| Novo Nordisk Inc | 14 | $155 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $90 |
| Ardelyx, Inc. | 4 | $90 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Dexcom, Inc. | 1 | $25 |
| Tris Pharma Inc | 1 | $21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $15 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
| GlaxoSmithKline, LLC. | 1 | $14 |
Products named: Wegovy, Kerendia, IBSRELA, VRAYLAR, Ozempic, QULIPTA, UBRELVY, Qelbree.
Industry payments across AL — which companies pay providers there.
